Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial

The study was designed to evaluate efficacy and superiority of capecitabine/bevacizumab + vinorelbine (CAP/BEV/VIN) compared to CAP/BEV alone. Main purpose was to introduce a taxane-/anthracycline-free first-line treatment in advanced breast cancer (ABC), in order to avoid long-term toxicities. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Welt, A., Marschner, N., Lerchenmueller, C., Decker, T., Steffens, C.-C., Koehler, A., Depenbusch, R., Busies, S., Hegewisch-Becker, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788680/
https://www.ncbi.nlm.nih.gov/pubmed/26927446
http://dx.doi.org/10.1007/s10549-016-3727-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788680/
https://www.ncbi.nlm.nih.gov/pubmed/26927446
http://dx.doi.org/10.1007/s10549-016-3727-x

Ejemplares similares